相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
Daniel Sanghoon Shin et al.
CANCER DISCOVERY (2017)
In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target
Robert T. Manguso et al.
NATURE (2017)
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
Angel Garcia-Diaz et al.
CELL REPORTS (2017)
Advances in immunotherapy for melanoma
Jason M. Redman et al.
BMC MEDICINE (2016)
Tumor-Intrinsic PD-L1 Signals Regulate Cell Growth, Pathogenesis, and Autophagy in Ovarian Cancer and Melanoma
Curtis A. Clark et al.
CANCER RESEARCH (2016)
Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy
Jianjun Gao et al.
CELL (2016)
Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade
Joseph L. Benci et al.
CELL (2016)
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Willy Hugo et al.
CELL (2016)
TC-PTP and PTP1B: Regulating JAK-STAT signaling, controlling lymphoid malignancies
Kelly A. Pike et al.
CYTOKINE (2016)
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Jesse M. Zaretsky et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
The YUMM lines: a series of congenic mouse melanoma cell lines with defined genetic alterations
Katrina Meeth et al.
PIGMENT CELL & MELANOMA RESEARCH (2016)
Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy
Douglas B. Johnson et al.
NATURE COMMUNICATIONS (2016)
Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells
Blanca Homet Moreno et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation
Giuseppe V. Masucci et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
Antitumour actions of interferons: implications for cancer therapy
Belinda S. Parker et al.
NATURE REVIEWS CANCER (2016)
Acquired resistance to immunotherapy and future challenges
Nicholas P. Restifo et al.
NATURE REVIEWS CANCER (2016)
Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade
Janis M. Taube et al.
CLINICAL CANCER RESEARCH (2015)
Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Relationship between immune gene signatures and clinical response to PD-1 blockade with pembrolizumab (MK-3475) in patients with advanced solid tumors
Mark Ayers et al.
Journal for ImmunoTherapy of Cancer (2015)
Acquired and intrinsic resistance in cancer immunotherapy
Sander Kelderman et al.
MOLECULAR ONCOLOGY (2014)
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh et al.
NATURE (2014)
Molecular Profiling of the Residual Disease of Triple-Negative Breast Cancers after Neoadjuvant Chemotherapy Identifies Actionable Therapeutic Targets
Justin M. Balko et al.
CANCER DISCOVERY (2014)
BRAF Mutations: Signaling, Epidemiology, and Clinical Experience in Multiple Malignancies
Richard D. Hall et al.
CANCER CONTROL (2014)
Activation of MAPK Pathways due to DUSP4 Loss Promotes Cancer Stem Cell-like Phenotypes in Basal-like Breast Cancer
Justin M. Balko et al.
CANCER RESEARCH (2013)
CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients
Patrick A. Ott et al.
CLINICAL CANCER RESEARCH (2013)
JAK/STAT signaling in hematological malignancies
W. Vainchenker et al.
ONCOGENE (2013)
The role of BRAF V600 mutation in melanoma
Paolo A. Ascierto et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2012)
Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance
Justin M. Balko et al.
NATURE MEDICINE (2012)
Combined MEK and EGFR inhibition demonstrates synergistic activity in EGFR-dependent NSCLC
Justin M. Balko et al.
CANCER BIOLOGY & THERAPY (2009)
Cross-regulation of Signaling Pathways by Interferon-γ: Implications for Immune Responses and Autoimmune Diseases
Xiaoyu Hu et al.
IMMUNITY (2009)
Molecular Mechanisms of IFN-gamma to Up-Regulate MHC Class I Antigen Processing and Presentation
Fang Zhou
INTERNATIONAL REVIEWS OF IMMUNOLOGY (2009)
STATs in cancer inflammation and immunity: a leading role for STAT3
Hua Yu et al.
NATURE REVIEWS CANCER (2009)
IFN-gamma signaling-Does it mean JAK-STAT?
Daniel J. Gough et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2008)
STAT5 contributes to interferon resistance of melanoma cells
C Wellbrock et al.
CURRENT BIOLOGY (2005)
Mechanisms of type-I- and type-II-interferon-mediated signalling
LC Platanias
NATURE REVIEWS IMMUNOLOGY (2005)
分享论文
